Study S001488

Does Glucagon-like Peptide (GLP-1) Receptor Agonist Stimulation Reduce Alcohol Intake in Patients With Alcohol Dependence?

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Statistical Analysis Plan (PDF)

Registration

Registration: NCT03232112
Acronym: EXALT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 152
Start: 2017-08-07
Primary completion: 2020-03-15
Lead sponsor: Anders Fink-Jensen, MD, DMSci
Conditions: Alcohol Dependence, in Remission; Addiction, Alcohol
Interventions: DRUG:Exenatide 2 MG Injection; DRUG:BD PosiFlush (saline)
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Heavy drinking days [30 days prior to baseline and 30 days prior to final follow up at 26 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012402	Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. Klausen MK, JCI insight	2022	Randomized trial	PMID 36066977 DOI	cites ClinicalTrials.gov:NCT03232112; registry reference DERIVED:36066977